Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Journal of Clinical Oncology · 01.01.2023 · 41 (1) · 132-142
DOI: 10.1200/jco.22.00710 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.01.2023. Verfasst von Carmelo Gurnari und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH. Hauptthemen laut MEDLINE: Anemia, Aplastic, Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
PURPOSE Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions. PATIENTS AND METHODS We studied a multicenter, retrospective cohort of 1,008 patients (median follow-up 8.6 years) with AA and PNH to assess clinical and molecular determinants of clonal evolution. RESULTS Although none of the patients transplanted upfront (n = 117) developed clonal complications (either sMN or secondary PNH), the 10-year cumulative incidence of sMN in nontransplanted cases was 11.6%. In severe AA, older age at presentation and lack of response to immunosuppressive therapy were independently associated with increased risk of sMN, whereas untreated patients had the highest risk among nonsevere cases. The elapsed time from AA to sMN was 4.5 years. sMN developed in 94 patients. The 5-year overall survival reached 40% and was independently associated with bone marrow blasts at sMN onset. Myelodysplastic syndrome with high-risk phenotypes, del7/7q, and ASXL1, SETBP1, RUNX1, and RAS pathway gene mutations were the most frequent characteristics. Cross-sectional studies of clonal dynamics from baseline to evolution revealed that PIGA/human leukocyte antigen lesions decreased over time, being replaced by clones with myeloid hits. PIGA and BCOR/L1 mutation carriers had a lower risk of sMN progression, whereas myeloid driver lesions marked the group with a higher risk. CONCLUSION The risk of sMN in AA is associated with disease severity, lack of response to treatment, and patients' age. sMNs display high-risk morphological, karyotypic, and molecular features. The landscape of acquired somatic mutations is complex and incompletely understood and should be considered with caution in medical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
- Department of Clinical Hematology, CHRU Nancy, Nancy, France.
- University of Paris, Paris, France.
- INSERM U 944/CNRS UMR 7212, Institut de Recherche Saint-Louis, Paris, France.
- Department of Medical Imaging, Hematology and Oncology, University of São Paulo, Riberão Preto, Brazil.
ORCID-Profile: Carmelo Gurnari, Simona Pagliuca, Pedro Henrique Prata, Jacques-Emmanuel Galimard, Luiz Fernando B Catto, Lise Larcher, Arda Durmaz, Andre L Pinto, Sophie Caillat-Zucman, Maria Teresa Voso, Gérard Socié, Jaroslaw P Maciejewski
Förderung
- NHLBI NIH HHS
Zitieren
APA
Gurnari, C., Pagliuca, S., Prata, P. H., Galimard, J. E., Catto, L. F. B., Larcher, L., Sebert, M., Allain, V., Patel, B. J., Durmaz, A., Pinto, A. L., Inacio, M. C. B., Hernandez, L., Dhedin, N., Caillat-Zucman, S., Clappier, E., Sicre de Fontbrune, F., Voso, M. T., Visconte, V., …, & Maciejewski, J. P. (2023). Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Journal of Clinical Oncology, 41(1), 132-142. https://doi.org/10.1200/jco.22.00710
Vancouver
Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L, et al. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Journal of Clinical Oncology. 2023;41(1):132-142. doi:10.1200/jco.22.00710
BibTeX
@article{Gurnari2023,
author = {Gurnari, Carmelo and Pagliuca, Simona and Prata, Pedro Henrique and Galimard, Jacques-Emmanuel and Catto, Luiz Fernando B and Larcher, Lise and Sebert, Marie and Allain, Vincent and Patel, Bhumika J and Durmaz, Arda and Pinto, Andre L and Inacio, Mariana C B and Hernandez, Lucie and Dhedin, Nathalie and Caillat-Zucman, Sophie and Clappier, Emmanuelle and Sicre de Fontbrune, Flore and Voso, Maria Teresa and Visconte, Valeria and Peffault de Latour, Régis and Soulier, Jean and Calado, Rodrigo T and Socié, Gérard and Maciejewski, Jaroslaw P},
title = {Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {1},
pages = {132--142},
doi = {10.1200/jco.22.00710}
}
EUVIMED